The option rights with Athera will not be exercised due to

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
The option rights with Athera will not be exercised due to re-evaluation of Boehringer Ingelheim’s R&D strategy – clinical development of Athera’s antibody proceeds as planned

Athera’s fully human monoclonal antibody PC-mAb is intended for the treatment of patients with cardiovascular disease, who are at an increased risk of secondary events and death. Boehringer Ingelheim’s decision to terminate the option agreement has been made as a consequence of a re-focus in its corporate R&D strategy. Athera’s ongoing Phase I study with PC-mAb will proceed as planned and the co-financing of future development costs through the EU FP7 program CARDIMMUN is not affected by Boehringer Ingelheim’s decision.

“Boehringer Ingelheim’s vast experience and resources within the cardiovascular field has significantly contributed to the successful progress of PC-mAb into the clinical development stage. We will now pursue work within the EU FP7 project CARDIMMUN, aiming to generate proof-of-activity data, and Athera will initiate activities to secure a new strategic partner for the later phases of clinical development and commercialization”, said Carina Schmidt, CEO of Athera Biotechnologies.

NOTE: Karolinska Development owns 65% of Athera Biotechnologies which includes indirect ownership through KCIF Co-Investment Fund KB.

For further information, please contact: Carina Schmidt, CEO, Athera Biotechnologies AB Phone: +46 76 193 81 90 e-mail: c.schmidt@athera.se

Bruno Lucidi, CEO, Karolinska Development AB Phone: +46 72 245 9892 e-mail: bruno.lucidi@karolinskadevelopment.com

 

TO THE EDITORS

About Athera Biotechnologies AB Athera has a unique and in-depth understanding of the immunological components in atherosclerosis, the inflammatory process leading to cardiovascular disease (CVD). The lead product candidate, PC-mAb, is in clinical development. PC-mAb is intended for the treatment of patients with cardiovascular disease, who are at an increased risk of secondary events and death. The current Phase I study will include up to 48 healthy volunteers in a single ascending dose protocol with safety outcome measures and is performed in Uppsala by CTC Clinical Trial Consultants AB. In addition, Athera has developed a biomarker and companion diagnostic CVDefine® kit. The biomarker, anti-PC, is linked to increased risk for cardiovascular disease and could in the future be used for identification of patients that benefit from Athera’s novel therapeutics. Future development costs for the antibody therapy will be co-financed by the EU FP7 program, in the project CARDIMMUN. The project, which has a total budget of nearly € 8 million, will run over 3 years and focus on the key preclinical and clinical development activities to show proof-of-activity in this new cardiovascular treatment. Partners in CARDIMMUN are Athera, Leiden University Medical Center (LUMC), Turku PET Center (Turku University), CTC Clinical Trial Consultants AB and Smerud Medical Research International AS. For more information, please visit www.athera.se.

 

About Karolinska Development AB Karolinska Development aims to create value for patients, researchers, investors and society by developing innovations from world class science into differentiated products that can be partnered. The business model is to: SELECT the most commercially attractive medical innovations that can potentially satisfy unmet medical needs; DEVELOP innovations to the stage where the greatest return on investment can be achieved; and COMMERCIALIZE the innovations through the sale of companies or out-licensing of products. An exclusive deal flow agreement with Karolinska Institutet Innovations AB, along with other cooperation agreements with leading universities, delivers a continuous flow of innovations. For more information, please visit www.karolinskadevelopment.com.

Karolinska Development is listed on NASDAQ OMX (KDEV). Karolinska Development may be required to disclose the information provided herein pursuant to the Securities Markets Act.

 

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Vuzix Bets on Lightweight Color Glasses for OEM Partners

Updated Category News Views 144

Forty grams is where this story gets interesting, because faces are ruthless product testers. People will tolerate plenty of clever technology right up until it pinches, looks goofy, leaks light, or makes them feel like they are wearing a science project. Vuzix is trying to clear that hurdle with Ultralite Color, a full-color AI eyewear reference platform built for OEM...

Continue Reading
Lotte's Songdo Plant 1 Puts 120,000 Liters on Deck

Updated Category News Views 95

A 120,000-liter biomanufacturing plant is not a ribbon-cutting trinket; it is a serious industrial bet that has to earn its keep one qualified batch at a time. LOTTE Biologics has completed Plant 1 at its Songdo Bio Campus in Incheon, South Korea, giving the company a sizable new production base as it tries to become a more consequential player in the global CDMO...

Continue Reading
Chaos Zero Nightmare's Award Is a Useful Signal for Games

Updated Category News Views 239

A story award can be easy to sneer at until a live-service game earns one across three markets. Smilegate's Chaos Zero Nightmare, a dark fantasy roguelike RPG developed by Super Creative, was named Best Story in Google Play's Best of 2026 awards for Taiwan, Hong Kong and Macau. That is not a sales figure, not a profit disclosure, and certainly not proof that a hit has...

Continue Reading
Parents Hand Kids Devices Years Before They Intended

Updated Category News Views 286

A nine-year-old with a smartphone used to raise eyebrows; this survey says it is increasingly the household baseline. All About Cookies, working with parental-control company Bark, surveyed U.S. parents and found that children typically receive personal devices well before their parents believe they should. That mismatch is not some cute little parenting contradiction. It...

Continue Reading
BetterInvesting Puts ELMD and FIVE Under a Fresh Lens

Updated Category News Views 74

Two familiar market traps are hiding in this otherwise useful announcement: mistaking a study candidate for a buy signal, and treating the word undervalued like it fell from a mountaintop. BetterInvesting has named Electromed Inc. as its “Stock to Study” and Five Below Inc. as its “Undervalued Stock” for the January-February 2027 issue of its magazine. That is...

Continue Reading
Kids First Data Sharing Raises Pediatric Research Bar

Updated Category News Views 73

Thirty-eight thousand children’s records are not a headline gimmick; they are a serious argument for treating research data as an asset that must keep working after the first study ends. The Gabriella Miller Kids First Data Resource Center’s ten-year review, published in the September 2026 issue of The American Journal of Human Genetics, makes that argument with...

Continue Reading
Leqembi’s Real-World Data Gives BioArctic More Weight

Updated Category News Views 121

A Harder Look at Treatment Staying Power Alzheimer’s drug data rarely arrive without a thicket of caveats, and that is exactly why this Leqembi update deserves a calm read rather than a victory lap. BioArctic’s partner Eisai presented a three-year real-world analysis at CTAD 2026 covering 560 early Alzheimer’s patients across 13 U.S. sites. The headline is striking:...

Continue Reading
MetaComp Targets ASEAN's Cross-Border Payment Snarl

Updated Category News Views 90

ASEAN payment plumbing is still a patchwork, and MetaComp is betting that patchwork has finally become painful enough to fix. The Singapore-based payments firm says its StableX Agentic Network has topped 1,000 members and reaches more than 100,000 users in its first year. That is a respectable early footprint, not a victory lap. Cross-border payments are littered with...

Continue Reading
Lake Ridge Sets $0.68 Dividend as 2026 Payouts Rise

Updated Category News Views 96

A community bank raising its cash return is not fireworks, but it gets my attention faster than another glossy growth slogan. Lake Ridge Bancorp has declared a fourth-quarter 2026 dividend of $0.68 per share, payable December 16 to shareholders of record on November 30. That is a plain, useful announcement from OTCQX:LRBI, and plain is often underrated when you are...

Continue Reading
FP Markets Puts Anthropic CFD Into the AI Trading Mix

Updated Category News Views 28

A fresh AI bellwether is about to meet the CFD crowd. FP Markets says it will add an Anthropic share CFD, identified as ANT.xnas, to its lineup on November 19, 2026. Clients worldwide are slated to access it through MetaTrader 5, cTrader, and TradingView. That is a tidy distribution expansion, but it lands with the usual AI-market fireworks already hissing in the...

Continue Reading

Top 5 Most Recently Viewed Articles

Trifork Group Launches 2025 Share-Based Incentive Program

Updated Category News Views 333

Trifork's Innovative Share-Based Incentive Program The Trifork Group AG has taken a significant step towards enhancing employee satisfaction and retention with the introduction of its Share-Based Incentive Program for 2025. This strategic decision supports Trifork’s ongoing commitment to fostering a motivated workforce and aligns with the company’s vision for growth...

Continue Reading
China's Agricultural Modernization: Dezhou's Vital Role

Updated Category News Views 40

Modern Farming Revolution in Dezhou Fifteen years ago, farming technology in Dezhou was a distant dream; today, it's a shining reality. Picture this: Song Zhijie, a veteran farmer, reflecting on a dusty 1997 summer harvest. Now, he sits in air-conditioned cabins, operating state-of-the-art machinery, basking in the efficiency that modern technology has granted. Dezhou, a...

Continue Reading
Exploring the Growth of the Cultured Wheat Market: 2024-2034

Updated Category News Views 142

Exploring the Growth of the Cultured Wheat Market The cultured wheat market is set for remarkable growth, with projections indicating an increase from USD 704.1 million in 2024 to USD 1,273.0 million by 2034. This growth translates to a solid compound annual growth rate (CAGR) of 6.1% over the decade. The rising demand for cultured wheat is driven by several factors,...

Continue Reading
Transforming Urban Mobility: Hikvision's AIoT Innovations

Updated Category News Views 292

Hikvision showcased its game-changing AIoT innovations at the ITS World Congress, zeroing in on making urban mobility safer, smarter, and greener. Their booth was abuzz with tech that’s not just flashy; it’s a serious play aimed at reshaping how we think about transport. The emphasis here? A commitment to road safety that's palpable, with cutting-edge solutions that...

Continue Reading
Avem Health Partners Welcomes Military Veterans to Board of Directors

Updated Category News Views 90

Enhancing Leadership at Avem Health Partners Avem Health Partners, a well-respected hospital management company based in Oklahoma City, is excited to announce the recent appointments of Keith Walker and Barbara Holcomb to its Board of Directors. This strategic decision aims to infuse the organization with a wealth of experience from both military and corporate...

Continue Reading